Complement Inhibition with the C5 Blocker LFG316 in Severe COVID-19.
- Resource Type
- letter
- Authors
- Zelek, Wioleta M.; Cole, Jade; Ponsford, Mark J.; Harrison, Richard A.; Schroeder, Ben E.; Webb, Nicholas; Jolles, Stephen; Fegan, Christopher; Morgan, Matt; Wise, Matt P.; Morgan, B. Paul
- Source
- American Journal of Respiratory & Critical Care Medicine; 11/1/2020, Vol. 202 Issue 9, p1304-1308, 5p
- Subject
- COVID-19
PATIENTS
DISEASES
BLOCKADE
COMPLEMENT (Immunology)
- Language
- ISSN
- 1073449X
The editor report on contribution of complement activation and impact of complement blockade in severe COVID-19. Topics include the C5-blocking mAb LFG316 could be administered in critically ill mechanically ventilated patients with COVID-19; and transient blockade of C5 is sufficient to interrupt the hyperinflammatory cycle in severe COVID-19.